AR 1002
Alternative Names: AR-1002Latest Information Update: 23 Nov 2023
At a glance
- Originator AriBio
- Developer AriBio; Columbia University
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Rett syndrome
Most Recent Events
- 25 Sep 2023 Preclinical trials in Alzheimer's disease in South Korea (unspecified route) before September 2023 (AriBio pipeline, September 2023)
- 25 Sep 2023 Preclinical trials in Rett syndrome in South Korea (unspecified route) before September 2023 (AriBio pipeline, September 2023)